ALX Oncology Holdings Inc. has announced the initiation of its Phase 1 clinical development program for ALX2004, following clearance of its Investigational New Drug $(IND.AU)$ application by the U.S. Food and Drug Administration in April 2025. ALX2004, a novel EGFR-targeted antibody-drug conjugate, is set to enter Phase 1 trials in mid-2025. The trial will focus on dose escalation in patients with EGFR-expressing solid tumors, including non-small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinoma. Initial safety data from the study is anticipated in the first half of 2026. ALX Oncology will provide further details on its clinical development plans and preclinical data in a webcast event. For more information, visit ALX Oncology's website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.